Disclosed is an isolated antibody, or antigen-binding fragment thereof, that: (a) binds to complement component human C5 (b) inhibits the cleavage of C5 into fragments C5a and C5b and (c) comprises: (i) a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO: 23, (ii) a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO: 19, (iii) a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO: 3, (iv) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO: 4, (v) a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO: 5, and (vi) a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO: 6, wherein the sequences are as defined in the complete specification. Further disclosed is the use of said antibody in the manufacture of a medicament for the treatment of a patient afflicted with a C5 mediated complement-associated condition.
